Company Overview - Shanghai Youningwei Biotechnology Co., Ltd. introduced its basic situation and 2024 operational performance during the investor relations activity [2]. Impact of Tariff Policies - The impact of increased tariffs on exports is minimal due to the low export ratio; however, it affects imports from the U.S. and promotes the development of the company's own brand [2]. Business Strategy for 2024 - The company will focus on a one-stop platform strategy and antibody strategy, increasing investment in R&D, promoting its own brand, and enhancing operational efficiency through information technology [2]. R&D Investment - In 2024, R&D investment reached CNY 62.77 million, a year-on-year increase of 7.10%, with R&D expenditure accounting for 5.62% of revenue [3]. Product Development - The company has significantly increased its product offerings, with over 2,900 products developed at the Nanjing Protein R&D Center and a nearly 30% year-on-year growth in revenue from its own brand in 2024 [3]. Share Buyback Program - In 2024, the company initiated a share buyback plan, utilizing CNY 25,987,076 to repurchase shares for employee stock ownership plans, aiming to enhance investor confidence and promote sustainable development [3]. Future Market Strategy - The company plans to enrich its product system and enhance both third-party and self-owned brand offerings, leveraging 20 years of experience in life sciences to provide comprehensive solutions to meet diverse customer needs [3].

其中以集中竞价交易方式减持在任意连续90日内，减持股份的总数不超过公司扣除回购专户股份后总股 本的1%；以大宗交易方式减持在任意连续90日内，减持股份的总数不得超过公司扣除回购专户股份后 总股本的2%。 上市次日，优宁维盘中创下股价最高点136元，此后股价震荡下跌。目前该股处于破发状态。 优宁维首次公开发行股票募集资金总额为18.65亿元，扣除发行费用后，募集资金净额为15.96亿元。优 宁维最终募集资金净额比原计划多13.12亿元。优宁维于2021年12月23日披露的招股说明书显示，公司 拟募集资金2.83亿元，计划分别用于线上营销网络与信息化建设项目、线下营销及服务网络升级项目、 研发中心建设项目、补充流动资金项目。 中国经济网北京4月23日讯优宁维（301166）(301166.SZ)昨日晚间披露公告称，股东上海创业接力泰礼 创业投资中心(有限合伙)(以下简称"泰礼投资")及其一致行动人上海泰礼创业投资管理有限公司-上海含 泰创业投资合伙企业(有限合伙)(以下简称"含泰投资")计划自减持计划公告披露之日起15个交易日后的3 个月内通过集中竞价或大宗交易的方式合计减持不超过2,572,172股，减持比例不 ...

Group 1 - The accounting policy change is in accordance with the latest accounting standards revised by the Ministry of Finance and will not have a significant impact on the company's financial status, operating results, or cash flow [1][2] - The board of directors believes that the accounting policy change is reasonable and does not harm the interests of the company and all shareholders [1][2] - The supervisory board also agrees that the accounting policy change is a reasonable adjustment that complies with relevant laws and regulations [2] Group 2 - The company announced the cancellation of part of the granted but unvested restricted stock from the 2022 incentive plan due to performance assessment not meeting the targets [10][12] - A total of 336,376 shares of restricted stock will be canceled, including 316,518 shares due to unmet performance targets and 18,188 shares due to the departure of nine incentive recipients [10][12] - The cancellation of these shares will not harm the interests of the company and all shareholders and will not significantly impact the company's financial status or operating performance [10][12] Group 3 - The company will hold the 2024 annual general meeting on May 13, 2025, at 14:30, with both on-site and online voting options available for shareholders [16][19] - The meeting will include voting on various proposals, with special resolutions requiring approval from at least two-thirds of the voting rights present [22][24] - Shareholders must register for the meeting in advance, with specific procedures outlined for both corporate and individual shareholders [25][26]

Core Viewpoint - The company, Shanghai Univey Biotech Co., Ltd., has conducted a self-evaluation of its internal control effectiveness as of December 31, 2024, and found no significant defects in both financial and non-financial reporting internal controls [3][34]. Internal Control Evaluation Conclusion - The board of directors concluded that the company has maintained effective internal controls over financial reporting in all significant aspects [3]. - No significant defects were identified in non-financial reporting internal controls as of the evaluation report date [3]. Internal Control Evaluation Work Situation Evaluation Scope - The evaluation scope was determined based on a risk-oriented principle, covering the company and its important subsidiaries, focusing on five main elements of internal control: internal environment, risk assessment, control activities, information and communication, and internal supervision [4]. Internal Environment - The company has established a governance structure in compliance with relevant laws and regulations, ensuring effective division of responsibilities and checks and balances [5][6]. - Internal audit functions are managed by the corporate management department, which oversees both internal and external audits [8]. Risk Assessment - The company has identified various internal risk factors, including management integrity, employee competence, and operational safety, and has established a risk management framework to address these risks [10][11]. Control Activities - The company has implemented control policies and procedures, including authorization management, segregation of incompatible duties, accounting system controls, asset protection controls, and independent auditing controls [13][14]. Information and Communication Control - A robust information and communication system has been established, ensuring effective information flow across departments and timely financial reporting [15]. Internal Control Defects Recognition and Rectification - The company has not identified any significant or important defects in internal controls during the reporting period [34]. Company Overview Main Business - The company provides life science reagents and related instruments, consumables, and comprehensive technical services, focusing on antibody-based products [38]. - It has integrated over 60 well-known brands and offers more than 9.7 million SKUs, covering various research areas in life sciences [38][41]. Operating Model - The company employs a dual procurement model, including stock procurement and sales-driven procurement, to meet the diverse needs of its clients [42]. - Sales are conducted through a nationwide network of subsidiaries and offices, complemented by an online platform [43][44]. Production Model - The company primarily acts as an agent for third-party brand products while also engaging in self-production through its subsidiaries [48][49]. Research and Development - The company focuses on innovative research and development based on customer needs, with dedicated teams for product and technology development [51][53].

证券代码：301166 证券简称：优宁维 公告编号：2025-036 上海优宁维生物科技股份有限公司 关于作废 2022 年限制性股票激励计划部分已授予 尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 20 日 召开第四届董事会第五次会议和第四届监事会第五次会议，审议通过了《关于作 废 2022 年限制性股票激励计划部分已授予尚未归属的限制性股票的议案》，现将 有关事项说明如下： 一、公司 2022 年限制性股票激励计划已履行的相关审批程序 1、2022 年 2 月 20 日，公司召开第三届董事会第三次会议，会议审议通过 了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公 司<2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会 授权董事会办理限制性股票激励计划相关事宜的议案》。公司独立董事就本次激 励计划相关议案发表了独立意见。 同日，公司召开第三届监事会第二次会议，审议通过了《关于公司<2022 年 限制 ...

上海优宁维生物科技股份有限公司 审计报告 立信中联审字[2025]D—0596 号 立信中联会计师事务所（特殊普通合伙） LixinZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) 目 录 | 一、 | 审计报告 | 1—5 | | --- | --- | --- | | 二、 | 财务报表 | | | 1、 | 合并资产负债表、母公司资产负债表 | 1—4 | | 2、 | 合并利润表、母公司利润表 | 5—6 | | 3、 | 合并现金流量表、母公司现金流量表 | 7—8 | | 4、 | 合并所有者权益变动表、母公司所有者权益变动表 | 9—12 | | 5、 | 财务报表附注 | 1—104 | 立信中联会计师事务所（特殊普通合伙） LixinZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) 审计报告 三、关键审计事项 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事 项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背景，我们不 对这些事项单独发表意见。 审计报告 第 1 页 立信中联审字[20 ...

上海市锦天城律师事务所 关于上海优宁维生物科技股份有限公司 2022 年限制性股票激励计划部分已授予 尚未归属的限制性股票作废事项的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海优宁维生物科技股份有限公司 2022 年限制性股票激励计划部分已授予 尚未归属的限制性股票作废事项的 法律意见书 致：上海优宁维生物科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海优宁维生物科技股 份有限公司（下称"优宁维"或"公司"）的委托，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深圳 证券交易所创业板股票上市规则》（以下简称"《创业板上市规则》"）以及《上 海优宁维生物科技股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，本所现就优宁维 2022 年限制性股票激励计划（以下简称"本 ...

民生证券股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：民生证券股份有限公司 | 被保荐公司简称：优宁维 | | --- | --- | | 保荐代表人姓名：孙银 | 联系电话：（021）60876732 | | 保荐代表人姓名：蒋红亚 | 联系电话：（021）60876732 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防 止关联方占用公司资源的制度、募集资金管理制度、内 | 是 | | 控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | ...

民生证券股份有限公司 关于上海优宁维生物科技股份有限公司 首次公开发行股票并在创业板上市之保荐总结报告书 上海优宁维生物科技股份有限公司（以下简称"优宁维"、"公司"或"发 行人"）于2021年12月28日在深圳证券交易所上市，持续督导期至2024年12月31日 止。民生证券股份有限公司（以下简称"民生证券"、"保荐机构"）作为公司 首次公开发行股票并在创业板上市的保荐机构，于上市之日起对公司进行持续督 导工作。目前持续督导期已经届满，现根据《证券发行上市保荐业务管理办法》、 《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第13 号——保荐业务》等有关法律法规和规范性文件的要求，出具本保荐总结报告书。 | 情况 | 内容 | | --- | --- | | 名称 | 民生证券股份有限公司 | | 法定代表人 | 顾伟 | | 注册地址 | 中国（上海）自由贸易试验区浦明路8号 | | 办公地址 | 中国（上海）自由贸易试验区浦明路8号 | | 保荐代表人 | 孙银、蒋红亚 | 四、保荐工作概述 （一）尽职推荐阶段 保荐机构遵守法律、法规及中国证监会、深圳证券交易所的有关规定，恪守 业务规 ...

上海优宁维生物科技股份有限公司 上海优宁维生物科技股份有限公司： 我们接受委托，对上海优宁维生物科技股份有限公司（以下简称"优宁维公 司"）2024 年度财务报表进行了审计，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度的合并及母公司利润表、合并及母公司现金流量表、合 并及母公司股东权益变动表，以及相关财务报表附注，并于 2025 年 4 月 20 日出 具立信中联审字[2025]D-0596 号审计报告。 关于营业收入扣除事项的 专项审核意见 立信中联专审字[2025]D—0148 号 立信中联会计师事务所（特殊普通合伙） LixinZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) 立信中联会计师事务所（特殊普通合伙） LixinZhonglian CPAs (SPECIAL GENERAL PARTNERSHIP) 关于营业收入扣除事项的 专项审核意见 立信中联专审字[2025]D-0148 号 立信中联专审字[2025]D-0148 号 （本页无正文，系上海优宁维生物科技股份有限公司《关于营业收入扣除事项的 专项审核意见》的签章页 ...